Trademark (99548138 8460 4480 B050 88a8f13a79de 00)
Levetiracetam
Product Images NDC 50090-3518
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-3518). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 02)
This formula depicts the calculation for creatinine clearance (CLcr), considering age, weight, serum creatinine, and a factor for female patients. It appears as a text panel showing the mathematical equation for estimating renal function.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 03)
An illustration showing the formula for calculating creatinine clearance normalized to body surface area. The formula expresses CLcr (mL/min/1.73m²) as the creatinine clearance (CLcr in mL/min) divided by the subject's body surface area (BSA in m²), multiplied by 1.73.*
Levetiracetam Structural Formula (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 04)
Chemical structure diagram of the active ingredient levetiracetam. The structure displays the molecular arrangement with a five-membered ring containing nitrogen, a ketone group, an amide group, and an ethyl side chain.*
Figure 1: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 1 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 05)
A bar chart titled 'Responder Rate (>50% Reduction From Baseline) In Study 1' displays the percentage of patients achieving this response in three groups: placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). Statistically significant differences versus placebo are noted for both Levetiracetam groups.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 06)
A bar chart titled 'Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A' depicting the percentage of patients responding to placebo and two dosages of Levetiracetam (1000 mg/day and 2000 mg/day). The percentages are approximately 6.3% for placebo, 20.8% for Levetiracetam 1000 mg/day, and 35.2% for Levetiracetam 2000 mg/day, with statistical significance indicated for both Levetiracetam groups compared to placebo.*
Figure 3: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Study 3 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 07)
A bar graph showing the responder rate defined as 50% or greater reduction from baseline in Study 3. The graph compares two groups: a Placebo group with 14.4% responder rate and a Levetiracetam 3000 mg/day group with a 39.4% responder rate. The difference is marked as statistically significant versus placebo.*
Figure 4: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 08)
A bar chart titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing the percentage of patients responding to Levetiracetam versus placebo. The chart shows approximately 19.6% response rate for placebo (N=97) and 44.6% for Levetiracetam (N=101), with a note indicating statistical significance versus placebo.*
Figure 5 (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 09)
Bar chart comparing the percentage of patients between placebo and Levetiracetam groups. The y-axis shows percentage of patients from 0% to 45%. The placebo group (N=51) shows approximately 19.6%, while the Levetiracetam group (N=58) shows about 43.1%, marked with an asterisk indicating statistical significance versus placebo.*
Figure 6: Responder Rate (greater Than Or Equal To 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week (F7b86151 8fdf 4bb8 8cd6 E6e24786df64 10)
A bar graph titled 'Responder Rate (≥50% Reduction from Baseline) in PGTC Seizure Frequency per Week in Study 7.' It compares the percentage of patients responding to placebo (45.2%) versus Levetiracetam (72.2%). The graph includes sample sizes (Placebo N=84; Levetiracetam N=79) and notes statistical significance between Levetiracetam and placebo groups.*
Label Image (Lbl500903518)
Levetiracetam tablet label from A-S Medication Solutions, listing product number 6722-0 and NDC 50090-3518-0. The label states each tablet contains levetiracetam, with storage instructions to keep tablets at 68 to 77 degrees Fahrenheit. The package contains 30 tablets. Additional text includes lot number and QR code for dosage information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
